12 min listen
Artificial Intelligence and the Journal of Clinical Psychopharmacology
Artificial Intelligence and the Journal of Clinical Psychopharmacology
ratings:
Length:
8 minutes
Released:
Sep 6, 2023
Format:
Podcast episode
Description
Much has been written in recent months regarding the growing use of artificial intelligence (AI) in medicine and the potential benefits and risks of its use. In this podcast, Anthony J. Rothschild, MD, Editor-in-Chief of the Journal of Clinical Psychopharmacology, highlights a paper in the journal by Drs. Jose de Leon and Carlos De Las Cuevas that reports their experiment to see how ChatGPT3 would respond to various questions about clozapine metabolism. The generated text proved to be profoundly unreliable. Dr. Rothschild also discusses his editorial about the journal’s policies regarding use of generative AI by authors and reviewers. Authors must disclose any such use; peer reviewers are prohibited from using AI in conducting their reviews. Dr. Rothschild’s editorial and the commentary by Drs. De Leon and de Las Cuevas both appear in the September–October 2023 issue of the Journal of Clinical Psychopharmacology.
Released:
Sep 6, 2023
Format:
Podcast episode
Titles in the series (41)
Why Is There No Food and Drug Administration–Approved Medication for Major Depression With Psychotic Features?: Psychotic depression is a severely disabling illness and is more common than is generally realized. Unfortunately, there is no FDA-approved medication for its treatment. In this podcast, the Editor-in-Chief of the Journal of Clinical... by The Journal of Clinical Psychopharmacology Podcast